On this page
Medicines have an established role
Medicines are usually the initial treatment pathway for TN. EAN recommends carbamazepine or oxcarbazepine for long-term treatment, while recognizing that symptom control and tolerability vary. These medicines influence nerve signalling; the term “anticonvulsant” describes their drug class and does not mean a TN diagnosis is epilepsy.12
The useful question is what the prescribed treatment has achieved for the person, including daily functioning and adverse effects. Tell the prescriber about other medicines, supplements and relevant health changes. A medicine name in a guideline is not enough to determine an individual regimen; the prescriber and pharmacist provide that plan.
Other and add-on approaches
When an initial medicine is unsuitable or insufficient, specialists may consider options such as lamotrigine, gabapentin, pregabalin or baclofen, alone or in combinations suited to the clinical situation. EAN also discusses botulinum toxin type A for selected cases, with weaker evidence and a different treatment role from first-line medicines. The supporting evidence is not equally strong for every option.1
Licensing and availability vary by health system. NHS information describes the UK setting and explains why a specialist may discuss a medicine used outside its specific licensed TN indication. That regional explanation should not be assumed to describe every country or every person's prescription.2
Tolerability needs follow-up
Carbamazepine can cause dizziness, tiredness, nausea and problems with coordination; serious reactions also occur. Discuss bothersome symptoms with the prescriber or pharmacist. A severe rash with blisters or mouth sores, or swelling of the throat or tongue with breathing difficulty, needs urgent emergency assessment through local services. The reference cannot tell whether a particular symptom is a drug reaction.3
Ask which monitoring applies to the proposed medicine, what interactions matter and whom to contact if symptoms worsen. Changes in pain, side effects, pregnancy plans or another treatment should be discussed with the team responsible for prescribing.
Severe deterioration and referral
EAN recognizes that severe exacerbations may require hospital care, including rehydration and specialist treatment. Pain that prevents adequate eating or drinking warrants prompt clinical help.1
A surgical opinion can be considered when pain control is inadequate or medicine is poorly tolerated. EAN does not require every possible drug to fail before referral. A consultation explains choices and consent; it is not a commitment to undergo a procedure.1
Support is part of care
RCS describes psychological and nursing support, pain-management services and patient support groups. TN-specific evidence for these programmes is limited, but care should acknowledge anxiety, disruption and the burden of living with pain. Support complements clinical treatment; it should not be presented as a proven replacement for it.4
For follow-up, bring an account of pain, medicines, tolerability and daily impact. Ask who coordinates care between appointments, when the plan will be reviewed and how to access help for an unexpected problem. Those practical arrangements make a prescribed plan usable without turning general reference information into individual treatment instructions.
References
- Bendtsen L et al. European Academy of Neurology guideline. Eur J Neurol. 2019;26:831–849. Source ↩
- NHS. Trigeminal neuralgia: treatment. Source ↩
- NHS. Carbamazepine (Tegretol). Source ↩
- McMillan R et al. Guidelines for the management of trigeminal neuralgia. RCS England Faculty of Dental Surgery, 2021. Source ↩